Cablivi

Cablivi is a medicine for use in adults and children from 12 years of age weighing at least 40 kg and who have an episode of acquired thrombotic thrombocytopenic purpura (aTTP), a blood clotting disorder. During an episode of aTTP, blood clots form in small blood vessels and the patient has a low count of platelets (components that help the blood to clot). Cablivi is used together with plasma exchange (a procedure that removes certain antibodies from the blood) and treatments to reduce the activity of the immune system (the body’s defences). Cablivi contains the active substance caplacizumab. aTTP is rare, and Cablivi was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 30 April 2009.